LONDON, January 28 /PRNewswire-FirstCall/ -- Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David Brennan saying in a video interview on http://www.cantos.com that cost control and restructuring had helped deliver a revenue line above company expectations.
In the video Mr Brennan looks at the results and the drivers behind a 23% rise in core operating profit and, significantly, a 12% dividend increase. He discusses the rationale behind the "significant" R&D changes that the company is implementing as well as progress on the ongoing restructuring programme and where he sees future growth and opportunities coming from.
While he says the next five years will be challenging, the long-term future looks strong.
"We're entering a period of time where we are launching new products and we're excited about them, but it's going to take a few years for those products to get up to the revenue contribution that we need that will balance some of the patent expirations."
The interview and transcript are available now on http://www.cantos.com/company/astrazeneca.
Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email firstname.lastname@example.org or phone +44-207-936-1352.
SOURCE AstraZeneca Plc